Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dalpiciclib + exemestane + goserelin
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Dalpiciclib + exemestane + goserelin is a combination therapy being investigated for HR-positive, HER2-negative breast cancer. This combination includes: - Dalpiciclib (SHR6390): A novel selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that works by blocking cell cycle progression - Exemestane: An aromatase inhibitor that reduces estrogen production - Goserelin: A gonadotropin-releasing hormone (GnRH) agonist that suppresses ovarian function This combination is specifically being studied as neoadjuvant therapy in premenopausal women with HR-positive, HER2-negative breast cancer.
- Brand names
- DarsilideDarxil
- Other names
- dalpiciclib + exemestane + gosserineDalpiciclib + Exemestane + Goserelin Neoadjuvant Therapy
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)CYP19A1 (Aromatase)
Beyond the preview
Go deeper on dalpiciclib + exemestane + goserelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dalpiciclib + exemestane + goserelin.